Faricimab lacks proof of added benefit over comparator therapies for macular edema

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion.

from News Medical Medical Research News Feed https://ift.tt/kQoVExq